Synapse
⌘+K
Sign In
Sign Up for Free
Synapse
Sign In
Sign Up for Free
Home
Communities
Explore
More
Language
English
English
Ultimovacs (Norway)
h-index: 8
Total citations: 307
Total papers: 26
Homepage:
http://ultimovacs.com/
Recent papers from Ultimovacs (Norway)
Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer
npj Precision Oncology · 2025
UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trial
Med · 2025
Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement
Molecular Therapy Oncology · 2025
Inflammatory signature and restriction of adaptive immunity are associated with unfavorable outcomes on immune checkpoint blockade in patients with advanced head and neck squamous cell carcinoma
2024
UV1 cancer vaccine in pembrolizumab-treated patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma: results from the randomized phase 2 FOCUS trial
2024
Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma.
Journal of Clinical Oncology · 2024
Abstract 7044: Transcriptome and TCR repertoire in human telomerase reverse transcriptase peptide vaccine treated metastatic prostate cancer patients
Cancer Research · 2024
Bridging responses to a human telomerase reverse transcriptase-based peptide cancer vaccine candidate in a mechanism-based model
International Immunopharmacology · 2023
Therapeutic cancer vaccination against telomerase: clinical developments in melanoma
Current Opinion in Oncology · 2023
Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination
Journal of Translational Medicine · 2022
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
Journal for ImmunoTherapy of Cancer · 2022
Personalized HLA typing leads to the discovery of novel HLA alleles and tumor‐specific HLA variants
HLA · 2022
Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential
Frontiers in Immunology · 2021
NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
Journal of Translational Medicine · 2021
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial
Frontiers in Immunology · 2021
Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer
Frontiers in Immunology · 2020
Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention
Toxicology Reports · 2020